Can DRL’s new product launches offset the slowdown in Revlimid sales ?
Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US business. The company launched 24 new products, with a pipeline of 100 products expected to offset slowing Revlimid sales. Analysts remain cautious, with (...)
Site référencé: The Economic Times
The Economic Times
Nifty consolidates between 25,700–26,100 ; Tata Steel, IIFL among top picks : Vinay Rajani
28/10/2025
Auto sector enters long-term growth cycle ; M&M, Maruti, Bajaj Auto among top picks : Sandip Sabharwal
28/10/2025
Inside Lenskart growth before IPO : Promising earnings at first glance or accounting gimmick ?
28/10/2025
Canara Robeco AMC shares crash 11% as Q2 net profit slips 20% to Rs 49 crore
28/10/2025
SBI, other PSU banks stocks rise up to 3% on reports of government move to raise FDI limit to 49%
28/10/2025
FII interest could revive India’s underperforming market : Sunil Koul
28/10/2025
